David Ricks, Eli Lilly CEO (Jeenah Moon/Bloomberg via Getty Images)
July 2, 2024 02:02 PM EDTUpdated 03:20 PM
Pharma
FDA+

Up­dat­ed: Eli Lil­ly wins long-await­ed ap­proval for Alzheimer’s drug

Ryan Cross

Senior Science Correspondent

Af­ter decades of try­ing to de­vel­op a treat­ment for Alzheimer’s dis­ease, Eli Lil­ly has fi­nal­ly won FDA ap­proval for its drug do­nanemab …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Pfiz­er’s mes­sage to in­vestors: The ship is steady­ing in 2025 (even if Wash­ing­ton is tur­bu­lent)

Jazz Phar­ma­ceu­ti­cals CEO and co-founder Bruce Cozadd is re­tir­ing

Chica­go’s biotech scene is grow­ing up. What’s fu­el­ing it?

Re­gen­eron looks to ex­pand la­bel of Eylea HD ear­ly next year

A service from the Financial Times